{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T08:14:06Z","timestamp":1788336846384,"version":"build-2803163510"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jdcr.2026.03.025","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T17:55:24Z","timestamp":1773942924000},"page":"234-238","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Bimekizumab for refractory hidradenitis suppurativa and associated inflammatory arthropathies"],"prefix":"10.1016","volume":"71","author":[{"given":"Christina","family":"Tolete","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reina","family":"Tolete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8925-1620","authenticated-orcid":false,"given":"Adam","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5661-5862","authenticated-orcid":false,"given":"Leonardo","family":"Tjahjono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jdcr.2026.03.025_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.humimm.2024.110764","article-title":"Differences in hidradenitis suppurativa patterns of cutaneous involvement between sexes: insights from a cross-sectional study","volume":"85","author":"Mintoff","year":"2024","journal-title":"Hum Immunol"},{"issue":"8","key":"10.1016\/j.jdcr.2026.03.025_bib2","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.3390\/cells10082094","article-title":"Hidradenitis suppurativa: where we are and where we are going","volume":"10","author":"Scala","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.jdcr.2026.03.025_bib3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jdin.2024.07.017","article-title":"Hidradenitis suppurativa is associated with inflammatory arthritis, systemic lupus erythematosus, and other autoimmune diseases: a retrospective population-level study","volume":"17","author":"Kassels","year":"2024","journal-title":"JAAD Int"},{"issue":"2","key":"10.1016\/j.jdcr.2026.03.025_bib4","article-title":"Prevalence of hidradenitis suppurativa in patients with axial spondyloarthritis","volume":"21","author":"Farran Ortega","year":"2025","journal-title":"Reumatol Clin (Engl Ed)"},{"issue":"1","key":"10.1016\/j.jdcr.2026.03.025_bib5","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jaad.2019.02.067","article-title":"North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part I: diagnosis, evaluation, and the use of complementary and procedural management","volume":"81","author":"Alikhan","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdcr.2026.03.025_bib6","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.12688\/f1000research.17267.1","article-title":"A systematic review and critical evaluation of inflammatory cytokine associations in hidradenitis suppurativa","volume":"7","author":"Frew","year":"2018","journal-title":"F1000Res"},{"issue":"5, Supplement","key":"10.1016\/j.jdcr.2026.03.025_bib7","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/j.jid.2023.03.515","article-title":"509 IL-17A and IL-17F in the pathogenesis of hidradenitis suppurativa: insights from early and chronic lesions","volume":"143","author":"Skelton","year":"2023","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jdcr.2026.03.025_bib8","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1136\/annrheumdis-2012-eular.2502","article-title":"FRI0045 Expression of IL-17A, IL-17F and their receptors in inflammatory arthritis: IL-17A expression in synovium and skin is differentially regulated by adalimumab","volume":"71","author":"van Baarsen","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.jdcr.2026.03.025_bib9","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.3899\/jrheum.190571","article-title":"Interleukin 17A and IL-17F expression and functional responses in rheumatoid arthritis and peripheral spondyloarthritis","volume":"47","author":"Chen","year":"2020","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.jdcr.2026.03.025_bib10","first-page":"185","article-title":"SAPHO syndrome associated with hidradenitis suppurativa successfully treated with infliximab and methotrexate","volume":"69","author":"De Souza","year":"2011","journal-title":"Bull NYU Hosp Jt Dis"},{"issue":"6","key":"10.1016\/j.jdcr.2026.03.025_bib11","doi-asserted-by":"crossref","first-page":"321","DOI":"10.5114\/reum.2016.64910","article-title":"Improvement of overlapping hidradenitis suppurativa and ankylosing spondylitis after the introduction of adalimumab","volume":"54","author":"Bosni\u0107","year":"2016","journal-title":"Reumatologia"},{"issue":"1","key":"10.1016\/j.jdcr.2026.03.025_bib12","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/jdv.20044","article-title":"Real-world adalimumab survival and discontinuation factors in hidradenitis suppurativa","volume":"39","author":"Garbayo-Salmons","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10370","key":"10.1016\/j.jdcr.2026.03.025_bib13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","article-title":"Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-alpha inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)","volume":"401","author":"Merola","year":"2023","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jdcr.2026.03.025_bib14","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1111\/ced.15237","article-title":"Does previous use of tumour necrosis inhibitors change the therapeutic effect of interleukin (IL)-17 or IL-12\/23 inhibitors on psoriasis and psoriatic arthritis? Results of a systematic review","volume":"47","author":"Xie","year":"2022","journal-title":"Clin Exp Dermatol"},{"issue":"10443","key":"10.1016\/j.jdcr.2026.03.025_bib15","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","article-title":"Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials","volume":"403","author":"Kimball","year":"2024","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jdcr.2026.03.025_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004464","article-title":"Bimekizumab provided rapid improvements in patient-reported symptoms and health-related quality of life in patients with active psoriatic arthritis: pooled 16-week results from two phase 3 studies","volume":"10","author":"Husni","year":"2024","journal-title":"RMD Open"},{"issue":"7","key":"10.1016\/j.jdcr.2026.03.025_bib17","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3899\/jrheum.2023-1085","article-title":"Defining the minimal important change and meaningful change value of the disease activity index for psoriatic arthritis: a Chinese longitudinal study","volume":"51","author":"Liu","year":"2024","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.jdcr.2026.03.025_bib18","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","article-title":"Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score","volume":"75","author":"Schoels","year":"2016","journal-title":"Ann Rheum Dis"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512626001566?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512626001566?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T07:22:32Z","timestamp":1788333752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512626001566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":18,"alternative-id":["S2352512626001566"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2026.03.025","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bimekizumab for refractory hidradenitis suppurativa and associated inflammatory arthropathies","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2026.03.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}